Literature DB >> 19003346

Relationship between antibody productivity by activated human lymph node lymphocytes from lung cancer patients and lymphocyte subsets.

K Yoshinari1, K Arai, K Matsumoto, H Kimura.   

Abstract

Regional lymph node lymphocytes from five patients with primary lung cancer were analyzed for subset composition, and exposed in vitro to the polyclonal human B cell mitogen Staphylococcus aureus Cowan I (SACI) or the murine B cell mitogen lipopolysaccharide (LPS) and then fused with mouse myeloma cells for investigation at the clonal level of their antibody (Ab) production and its statistical relation to the original subset composition. No correlation was found between the proportion of CD19+, CD23+, or CD3+ cells in the lymphocyte sample prior to its exposure to either SACI or LPS, and the Ab production efficiency, defined as the ratio of the number of Ab producing wells to the total number of proliferating wells. For lymphocytes exposed to LPS, however, a strong correlation (r = 0.931, p = 0.02) was observed between the Ab production efficiency and the ratio of CD8+ to CD3+ cells (CD8/CD3) in the original sample at least within the ranges studied (CD8/CD3 = 0.216-0.288). For those exposed to SACI, no correlation was found between the Ab production efficiency and the CD8/CD3 ratio (r = 0.881, p = 0.12) or the proportion of CD8+ cells (r = 0.808, p = 0.19) in the original sample. These results suggest that the repertoire of B cells responsive to LPS is different at least in part from the repertoire responsive to SACI and that the ratio CD8/CD3 could serve as a practical predictor for Ab production by human lymphocytes stimulated with LPS.

Entities:  

Year:  1999        PMID: 19003346      PMCID: PMC3463393          DOI: 10.1023/A:1008052326963

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  25 in total

1.  Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients.

Authors:  T B Kjeldsen; B B Rasmussen; C Rose; J Zeuthen
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

Review 2.  CD14: cell surface receptor and differentiation marker.

Authors:  H W Ziegler-Heitbrock; R J Ulevitch
Journal:  Immunol Today       Date:  1993-03

3.  Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.

Authors:  S Tsujitani; M Nakashima; T Watanabe; N Kaibara; H Koprowski; Z Steplewski
Journal:  Anticancer Res       Date:  1995 May-Jun       Impact factor: 2.480

4.  HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.

Authors:  M Nakashima; T Watanabe; H Koprowski; Z Steplewski
Journal:  Hybridoma       Date:  1996-04

5.  Activation of human B and T lymphocytes by protein A of Staphylococcus aureus.

Authors:  O Ringdén
Journal:  Eur J Immunol       Date:  1978-01       Impact factor: 5.532

6.  Long-term production of human monoclonal antibodies by human-mouse heterohybridomas.

Authors:  K Yoshinari; K Arai; H Kimura; K Matsumoto; Y Yamaguchi
Journal:  J Immunol Methods       Date:  1995-10-12       Impact factor: 2.303

7.  Lymphocyte subset alterations in nodes regional to human melanoma.

Authors:  Z Farzad; A J Cochran; W H McBride; J D Gray; V Wong; D L Morton
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

9.  Staphylococcus aureus Cowan I-induced immunoglobulin production in human cord blood lymphocytes.

Authors:  O Ruuskanen; W B Pittard; K Miller; G Pierce; R U Sorensen; S H Polmar
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

10.  Human monoclonal antibodies directed against melanoma tumor-associated antigens.

Authors:  J Kan-Mitchell; A Imam; R A Kempf; C R Taylor; M S Mitchell
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.